Study of NM8074 for dermatomyositis
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests a new medicine called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rash. The goal is to see if it can help reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of probable or definite dermatomyositis.
- Your body mass index (BMI) must be between 15 and 38.
- You need to have had certain vaccinations before starting the study, or be willing to take antibiotics as a precaution.
- You must agree to use birth control during and for 8 weeks after the study if you are of childbearing age.
- You cannot have certain other medical conditions, like active infections, recent cancer, or organ transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment made from mitochondria (the energy centers of cells) for people with polymyositis or dermatomyositis that hasn't improved with standard treatments. It aims to see if the treatment is safe and can help reduce muscle weakness and other symptoms.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.